These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30312633)

  • 1. Chronic co-administration of nalbuphine attenuates the development of opioid dependence.
    Raghav R; Jain R; Dhawan A; Roy TS; Kumar P
    Pharmacol Biochem Behav; 2018 Dec; 175():130-138. PubMed ID: 30312633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-administration of nalbuphine attenuates the morphine-induced anxiety and dopaminergic alterations in morphine-withdrawn rats.
    Raghav R; Jain R; Jacob TG; Dhawan A; Roy TS
    Psychopharmacology (Berl); 2021 Apr; 238(4):1193-1211. PubMed ID: 33655408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nalbuphine coadministered with morphine prevents tolerance and dependence.
    Lee SC; Wang JJ; Ho ST; Tao PL
    Anesth Analg; 1997 Apr; 84(4):810-5. PubMed ID: 9085963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuation of morphine tolerance and withdrawal syndrome by coadministration of nalbuphine.
    Jang S; Kim H; Kim D; Jeong MW; Ma T; Kim S; Ho IK; Oh S
    Arch Pharm Res; 2006 Aug; 29(8):677-84. PubMed ID: 16964763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nalbuphine.
    Schmidt WK; Tam SW; Shotzberger GS; Smith DH; Clark R; Vernier VG
    Drug Alcohol Depend; 1985 Feb; 14(3-4):339-62. PubMed ID: 2986929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nalbuphine is effective in decreasing the rewarding effect induced by morphine in rats.
    Tao PL; Liang KW; Sung WY; Wu YT; Huang EY
    Drug Alcohol Depend; 2006 Sep; 84(2):175-81. PubMed ID: 16517095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of opioid agonist and antagonist in dams exposed to morphine during the perinatal period.
    Sobor M; Timár J; Riba P; Friedmann T; Király KP; Gyarmati S; Al-Khrasani M; Fürst S
    Brain Res Bull; 2011 Jan; 84(1):53-60. PubMed ID: 20934489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
    Rehni AK; Bhateja P; Singh TG; Singh N
    Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GABA and opioid mechanisms of the central amygdala underlie the withdrawal-potentiated startle from acute morphine.
    Cabral A; Ruggiero RN; Nobre MJ; Brandão ML; Castilho VM
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):334-44. PubMed ID: 19150477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonist effects of nalbuphine in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Mar; 248(3):929-37. PubMed ID: 2467983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The analgetic effects of an intrathecally administered partial opiate agonist, nalbuphine hydrochloride.
    Schmauss C; Doherty C; Yaksh TL
    Eur J Pharmacol; 1982 Dec; 86(1):1-7. PubMed ID: 6897635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of opioid agonist and agonist-antagonist: patient-controlled analgesia requirement and adverse events among different-ratio morphine and nalbuphine admixtures for postoperative pain.
    Yeh YC; Lin TF; Lin FS; Wang YP; Lin CJ; Sun WZ
    Br J Anaesth; 2008 Oct; 101(4):542-8. PubMed ID: 18640992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone attenuates the opioid withdrawal and vulnerability to relapse to heroin seeking in rodents.
    de Guglielmo G; Kallupi M; Scuppa G; Demopulos G; Gaitanaris G; Ciccocioppo R
    Psychopharmacology (Berl); 2017 Jan; 234(2):223-234. PubMed ID: 27714428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain.
    Fan LW; Tanaka S; Tien LT; Ma T; Rockhold RW; Ho IK
    Brain Res Bull; 2002 Jun; 58(2):149-60. PubMed ID: 12127012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of low-dose nalbuphine and morphine in patient-controlled analgesia decreases incidence of opioid-related side effects.
    Yeh YC; Lin TF; Chang HC; Chan WS; Wang YP; Lin CJ; Sun WZ
    J Formos Med Assoc; 2009 Jul; 108(7):548-53. PubMed ID: 19586828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prodynorphin gene deficiency potentiates nalbuphine-induced behavioral sensitization and withdrawal syndrome in mice.
    Shin EJ; Jang CG; Bing G; Park DH; Oh CH; Koo KH; Oh KW; Yamada K; Nabeshima T; Kim HC
    Drug Alcohol Depend; 2009 Sep; 104(1-2):175-84. PubMed ID: 19559544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
    Raehal KM; Lowery JJ; Bhamidipati CM; Paolino RM; Blair JR; Wang D; Sadée W; Bilsky EJ
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1150-62. PubMed ID: 15716384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tizanidine administration on precipitated opioid withdrawal signs in rats.
    Pinelli A; Trivulzio S; Spezia R
    Drug Alcohol Depend; 1998 Mar; 50(1):81-8. PubMed ID: 9589275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the subjective, psychomotor and physiological effects of intravenous nalbuphine and morphine in healthy volunteers.
    Zacny JP; Conley K; Marks S
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1159-69. PubMed ID: 9067299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal kappa-opioid receptor-mediated dependence and withdrawal in the nucleus paragigantocellularis.
    Sinchaisuk S; Ho IK; Rockhold RW
    Pharmacol Biochem Behav; 2002 Dec; 74(1):241-52. PubMed ID: 12376173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.